The effect of the non-ionic contrast medium iohexol on glomerular and tubular function in diabetic patients.
The effect of the non-ionic contrast medium iohexol (Omnipaque) on renal function was investigated in diabetic patients with signs of peripheral ischaemia. Forty-six patients, 70 +/- 11 years (mean +/- SD) old, age at diabetes diagnosis 53 +/- 17 years, and with varying degrees of diabetic nephropathy were studied before 1, 2, and 30 days after aortobifemoral arteriography. Serum creatinine, creatinine clearance, urinary excretion of immunoglobulin G, albumin collagen IV (NC1), kappa and lambda chains, alpha-1 microglobulin and Tamm-Horsfall protein were evaluated. Within 1 month before and 30 days after arteriography, the glomerular filtration rate was measured by clearance of iohexol. The acute effect of the radiocontrast medium was an increase in the serum creatinine level in 41 (89%) patients, with a more than 25% increase in 12 (26%) patients. The excretion rates of immunoglobulin G and albumin decreased, whereas the proximal and distal tubular function and the excretion of collagen IV did not change. The increment in serum creatinine was associated with the preangiographic renal function (p < 0.05), a history of heart failure (p < 0.01), but not with age, duration and type of diabetes, gender, systolic or diastolic blood pressure, glycated haemoglobin (HbAlc) or blood glucose levels. The increase of serum creatinine was associated with a pre-existing proximal tubular dysfunction and a worsening of distal tubular function. No changes in the parameters measured persisted 30 days after angiography. In summary, a transient increment in serum creatinine level after arteriography occurred in 89% of diabetic patients. It was associated with the preangiographic renal function, a history of heart failure and signs of preexisting proximal tubular dysfunction and worsening of distal tubular function. However, these changes were reversible.
Apelqvist
J
J
Department of Internal Medicine, University Hospital of Lund, Sweden.
Torffvit
O
O
Agardh
C D
CD
D017668:Age of Onset; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure; D003287:Contrast Media / Q000493:pharmacokinetics / Q000494:pharmacology*; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000097:blood / Q000000981:diagnostic imaging / Q000503:physiopathology*; D005260:Female; D005919:Glomerular Filtration Rate; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007472:Iohexol / Q000493:pharmacokinetics / Q000494:pharmacology*; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000503:physiopathology; D007684:Kidney Tubules / Q000187:drug effects* / Q000503:physiopathology; D007686:Kidney Tubules, Distal / Q000187:drug effects / Q000503:physiopathology; D007687:Kidney Tubules, Proximal / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008657:Metabolic Clearance Rate; D011859:Radiography
D001786:Blood Glucose; D003287:Contrast Media; D003404:Creatinine; D006442:Glycated Hemoglobin; D007472:Iohexol